Calcium-binding proteins (CaBPs) are known to modulate neuronal excitability and calcium signaling, and they may play a role in the imbalances of excitation and inhibition of temporal lobe epilepsy (TLE). While parvalbumin and calretinin are well-characterized CaBPs, N-Terminal EF-Hand Calcium-Binding Protein 1 (NECAB1) remains understudied in epilepsy, despite its association with neurodegenerative conditions. In this study, we used fluorescent immunolabeling to determine the distribution of NECAB1, as well as its co-expression with parvalbumin and calretinin, in brain regions associated with the epileptic circuitry using a kainic acid-induced TLE model. Additionally, we examined the impact of levetiracetam and brivaracetam on NECAB1 expression. In our study, NECAB1-positive cells were prominently localized to the paraventricular nucleus of the thalamus (PVT), endopiriform nucleus (EPN), and amygdala in healthy brain regions involved in epileptic circuitry. A NECAB1–calretinin co-expressing subpopulation was detected in the amygdala, PVT, and hippocampus but was nearly absent in the EPN. In chronic epilepsy, NECAB1 expression was significantly upregulated in the PVT and bilaterally in the amygdala. These findings suggest that NECAB1 upregulation may compensate for epileptic hyperexcitability, potentially contributing to circuit remodeling via thalamocortical regulation and interneuron diversity. Levetiracetam and brivaracetam treatments partially reduced the NECAB1 density increase in TLE, indicating a modulatory effect on NECAB1 expression.
Temporal lobe epilepsy (TLE) is increasingly conceptualized not as an isolated hippocampal lesion, but as a complex, multiscale limbic network connectomic disorder. Despite advances in pharmacological management, over 30% of patients experience drug-resistant epilepsy, underscoring the urgent need to shift from symptomatic seizure control to mechanism-directed disease modification. This review comprehensively synthesizes the pathophysiological architecture of epileptogenesis in TLE, spanning mitochondrial bioenergetic alterations, chronic neuroinflammation, synaptic reorganization, and ionic plasticity resulting from ion-channel dysregulation. We evaluate diagnostic advancements, highlighting how invasive stereo-EEG disambiguates pathological high-frequency oscillations from physiological ripples, how structural HARNESS-MRI maps anatomical substrates, and how AI-driven algorithms analyze ultra-long-term EEG streams for continuous seizure forecasting. Additionally, peripheral biofluid proteins and microRNAs provide noninvasive windows into active neuroinflammation and network remodeling, serving as valuable tools for longitudinal disease monitoring rather than primary screening. Therapeutically, the field is evolving beyond empirical antiseizure medications toward mechanism-based rational drug design and precision interventions. Dual-mechanism agents enhance seizure freedom, while antisense oligonucleotides, microRNA antagomirs, and cation-chloride cotransporter modulators target underlying genetic and biophysical drivers. Minimally invasive ablation, AI-guided closed-loop neuromodulation, targeted anti-inflammatory biologics, and patient-derived 3D cerebral organoid platforms further expand the translational frontier. Ultimately, bridging these experimental modalities through prospective clinical validation may provide a viable path toward interrupting epileptogenesis and realizing true disease modification in human TLE.